Supplemental material
Open access
2,667
Views
2
CrossRef citations to date
0
Altmetric
Zoster
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Ru Hana Value Evidence Outcome Department, GSK, Wavre, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0002-4851-1462View further author information
Jorge A. Gomezb Value Evidence Outcome Department, GSK, Buenos Aires, Argentina
https://orcid.org/0000-0001-5459-4973View further author information
Bruna de Verasc Value Evidence Outcome Department, GSK, Rio de Janeiro, Brazil
https://orcid.org/0000-0002-7927-050XView further author information
Thatiana Pintoa Value Evidence Outcome Department, GSK, Wavre, Belgium
https://orcid.org/0000-0002-0957-3118View further author information
Adriana Guzman-Holsta Value Evidence Outcome Department, GSK, Wavre, Belgium
https://orcid.org/0000-0002-6753-2541View further author information
Javier Nietod Medical Affairs Department, GSK, Panama City, Panama
https://orcid.org/0000-0002-3073-2830View further author information
Désirée A. M. van Oorschota Value Evidence Outcome Department, GSK, Wavre, Belgium
https://orcid.org/0000-0002-0382-0333View further author information
Article: 2164144
|
Received 02 Nov 2022, Accepted 28 Dec 2022, Published online: 23 Feb 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.